# Oncimmune Holdings plc University of Nottingham share sale

- Link: https://www.directorstalkinterviews.com/oncimmune-holdings-plc-university-nottingham-share-sale/412745110
- Published: 2018-02-05T07:13:56+00:00
- Author: Giles Arbor

**Oncimmune Holdings plc** (LON:ONC), a leading early cancer detection company spun
out of the University of Nottingham to develop and commercialise its proprietary
EarlyCDT® liquid biopsy platform technology, noted today the sale of 4,317,287 shares
by the University. The University will remain a holder of 2,244,527 shares following
its sale and has agreed to extend its lock up of these remaining shares for a further
six months. The sale of these shares by the University is another step along the
path of a successful spin out of the university technology.

> **Geoffrey Hamilton-Fairley, CEO of Oncimmune Holdings Plc, commented:** “Today’s
> announcement is a natural evolution of our shareholder register as the University
> of Nottingham, where Oncimmune’s EarlyCDT® platform technology was invented, realises
> the value of part of their shareholding. Oncimmune still has ties to the University
> and we are grateful to them for their role in the origin of EarlyCDT® platform.
> We are delighted that they retain part of their holding and we look forward to
> realising further value from our liquid biopsy platform which can detect up to
> four years earlier than other methods.”
> **Dr Andrew Naylor, CEO of Nottingham Technology Ventures Ltd which manages the
> University of Nottingham’s spin-out portfolio, said:** “Today’s sale of shares
> represents a significant return on our original investment in Oncimmune and the
> Company is an exemplar of what can be done when a technology is successfully spun
> out from the University of Nottingham. It has been a pleasure to see Oncimmune
> grow into a leading early cancer detection company that is already saving lives
> and is on track to save many more. We look to the future with confidence as the
> Company has the Management and strategy in place to deliver value and we are delighted
> to retain a significant shareholding.”

Oncimmune is a leading early cancer detection company developing and commercialising
its proprietary EarlyCDT® platform technology. Oncimmune has pioneered the development
of autoantibody tests that can detect cancer up to four years earlier than other
methods and can be applied to a very wide range of solid tumour types. The Company’s
first product, EarlyCDT®-Lung, was launched in 2012, as a CLIA test in the USA and
since then over 150,000 commercial tests have been sold. EarlyCDT®-Lung is available
through physicians in the US and also privately in the UK and other regions. EarlyCDT
®-Lung is being used in the largest ever randomised trial for the early detection
of lung cancer using biomarkers, the National Health Service (NHS) Scotland ECLS
study of 12,210 high-risk smokers. EarlyCDT® tests for liver and ovarian cancer 
are in development.

Share on:
